Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.

AIDS (London, England) - 13 Nov 2010

Charpentier Charlotte, Larrouy Lucile, Collin Gilles, Damond Florence, Matheron Sophie, Chêne Geneviève, Nie Ting, Schinazi Raymond, Brun-Vézinet Françoise, Descamps Diane

Abstract excerpt

In this study of nine clinical isolates obtained from integrase inhibitor-naïve HIV-2-infected patients, the median EC₅₀ value for the new integrase inhibitor S/GSK1349572 was 0.8 nM (range 0.2-1.4), and is similar to HIV-1 reference strains. We found a seven-, 13- and 18-fold increase in EC₅₀ va...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV-2
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Integrase Inhibitors

Share to HIV Research and Treatment

Share to Mutation

Share to Pneumocystis jirovecii pneumonia detection and treatment

Source

Identifiers

PMID: 20827161
DOI: 10.1097/QAD.0b013e32833f9e36

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20827161-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.PMID 20827161Read ↗

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.Semantic proximity Read ↗

HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.Semantic proximity Read ↗

HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase MutantsSemantic proximity Read ↗

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.Semantic proximity Read ↗

Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.Semantic proximity Read ↗

Anti-HIV-1 Activity of the Integrase Strand Transfer Inhibitor ACC017.Semantic proximity Read ↗

In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.Semantic proximity Read ↗

Resistance to HIV-1 integrase inhibitors: A structural perspective.Semantic proximity Read ↗

Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical IsolatesSemantic proximity Read ↗

Systematic determination of in vitro phenotypic resistance to HIV-1 integrase strand transfer inhibitors from clinical samplesSemantic proximity Read ↗

Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.Semantic proximity Read ↗

Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.